Accelerating precision medicine in metastatic prostate cancer.

Early Detection of Cancer Humans Male Medical Oncology Precision Medicine Prostate-Specific Antigen Prostatic Neoplasms / diagnosis

Journal

Nature cancer

ISSN: 2662-1347

Titre abrégé: Nat Cancer

Pays: England

ID NLM: 101761119

Informations de publication

Date de publication:
11 2020

Historique:

entrez: 14 7 2021

pubmed: 15 7 2021

medline: 15 7 2021

Statut: ppublish

Résumé

Despite advances in prostate cancer screening and treatment, available therapy options, particularly in later stages of the disease, remain limited and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in significant variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach to identify patients whose tumors exhibit actionable targets and make more informed treatment decisions. Here we discuss how we can accelerate precision oncology to inform broader genomically-driven clinical decisions for men with advanced prostate cancer, drug development and ultimately contribute to new treatment paradigms.

Identifiants

DOI: 10.1038/s43018-020-00141-0 PMID: 34258585 PMC: PMC8274325

pubmed: 34258585

doi: 10.1038/s43018-020-00141-0

pmc: PMC8274325

mid: NIHMS1673984

pii: 10.1038/s43018-020-00141-0

doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Pagination

1041-1053

Subventions

Organisme : NCI NIH HHS

ID : R37 CA241486

Pays : United States

Déclaration de conflit d'intérêts

Competing Interests Statement. J.M. reports advisory board participation for Amgen, AstraZeneca, Roche, Janssen, MSD and Clovis Oncology; research funding from AstraZeneca and Pfizer Oncology; W.A. reports consulting /advisory for Clovis, Janssen, More Health, ORIC, Daiichi Sankyo; research funding from AstraZeneca, Zenith Epigenetics, Clovis, GlaxoSmithKline, ORIC, Epizyme; travel from GlaxoSmithKline, Clovis, ORIC; and honoraria from CARET. R.R.M. received research funding from Bayer, Pfizer, Tempus; serves on Advisory Board for Bayer, Bristol Myers Squib, Exelixis, Janssen, Novartis, Pfizer, Sanofi, Tempus; is a consultant for Dendreon, Vividion. R.A. reports advisory board participation and research funding from Merck, AstraZeneca, and Janssen; B.M. reports research funding from AstraZeneca, Janssen, Clovis, Astellas, Beigene; M.R. reports consulting: Amgen, Ambryx, Constellation; educational writing and consulting: Plexus; speaking: Bayer, Janssen; funding and clinical research support: Novartis, Astellas, Medivation, Merck; D.B.S. has consulted for/received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, BioBridge, Vivideon Therapeutics, and Illumina; E.V. reports advisory/consulting: Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio, Monte Rosa; research support: Novartis, BMS; Equity: Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft, Monte Rosa; travel reimbursement: Roche/Genentech; institutional patents on chromatin mutations and immunotherapy response, and methods for clinical interpretation; D.V. reports honoraria from Clovis Oncology. H.B. reports advisory/consulting from Janssen, Amgen, Astra Zeneca, Pfizer, Astellas, Sanofi Genzyme and research funding from Janssen, Abbvie Stemcentryx, Eli Lilly, Millenium, Astellas. J.V. is employed by the Prostate Cancer Clinical Trials Consortium. H.R.S., J.W.S., and A.K.M. are employed by the Prostate Cancer Foundation.

Références

Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).

pubmed: 30207593

Eggener, S. E. et al. Molecular biomarkers in localized prostate cancer: ASCO guideline. J. Clin. Oncol. 38, 1474–1494 (2020).

pubmed: 31829902 doi: 10.1200/JCO.19.02768

Sonni, I. et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J. Nucl. Med. 61, 1153–1160 (2020).

pubmed: 31924715 doi: 10.2967/jnumed.119.237602 pmcid: 7413232

Klotz, L. et al. Active Surveillance Magnetic Resonance Imaging Study (ASIST): results of a randomized multicenter prospective trial. Eur. Urol. 75, 300–309 (2019).

pubmed: 30017404 doi: 10.1016/j.eururo.2018.06.025

Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).

pubmed: 29552975 doi: 10.1056/NEJMoa1801993

Ku, S. Y., Gleave, M. E. & Beltran, H. Towards precision oncology in advanced prostate cancer. Nat. Rev. Urol. 16, 645–654 (2019).

pubmed: 31591549 pmcid: 6858516 doi: 10.1038/s41585-019-0237-8

Gandaglia, G. et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74, 210–216 (2014).

pubmed: 24132735 doi: 10.1002/pros.22742

Halabi, S. et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J. Clin. Oncol. 34, 1652–1659 (2016).

pubmed: 26951312 pmcid: 4872320 doi: 10.1200/JCO.2015.65.7270

Scher, H. I. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J. Clin. Oncol. 34, 1402–1418 (2016).

pubmed: 26903579 pmcid: 4872347 doi: 10.1200/JCO.2015.64.2702

Perez-Lopez, R. et al. Multiparametric magnetic resonance imaging of prostate cancer bone disease: correlation with bone biopsy histological and molecular features. Invest. Radiol. 53, 96–102 (2018).

pubmed: 28906339 pmcid: 5768227 doi: 10.1097/RLI.0000000000000415

Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 22, 232–240 (1972).

pubmed: 4625049 doi: 10.3322/canjclin.22.4.232

Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33–39 (2004).

pubmed: 14702632 doi: 10.1038/nm972

Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015).

pubmed: 26563462 pmcid: 4771416 doi: 10.1038/nrc4016

Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

pubmed: 23228172 doi: 10.1056/NEJMoa1209096

de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

pubmed: 21612468 pmcid: 3471149 doi: 10.1056/NEJMoa1014618

Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

pubmed: 22894553 doi: 10.1056/NEJMoa1207506

Beer, T. M. & Tombal, B. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).

pubmed: 24881730 pmcid: 4418931 doi: 10.1056/NEJMoa1405095

Hussain, M. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 378, 2465–2474 (2018).

pubmed: 29949494 doi: 10.1056/NEJMoa1800536 pmcid: 8288034

Fizazi, K. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 380, 1235–1246 (2019).

pubmed: 30763142 doi: 10.1056/NEJMoa1815671

Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13–24 (2019).

pubmed: 31150574 doi: 10.1056/NEJMoa1903307

Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).

pubmed: 28578607 doi: 10.1056/NEJMoa1704174

James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).

pubmed: 28578639 pmcid: 5533216 doi: 10.1056/NEJMoa1702900

Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019).

pubmed: 31157964 doi: 10.1056/NEJMoa1903835

Attard, G. et al. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J. Clin. Oncol. 36, 2639–2646 (2018).

pubmed: 30028657 pmcid: 6118405 doi: 10.1200/JCO.2018.77.9827

Rathkopf, D. E. et al. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin. Cancer Res. 23, 3544–3551 (2017).

pubmed: 28213364 pmcid: 5543693 doi: 10.1158/1078-0432.CCR-16-2509

Beltran, H. et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin. Cancer Res. 25, 6916–6924 (2019).

pubmed: 31363002 pmcid: 6891154 doi: 10.1158/1078-0432.CCR-18-1912

Beltran, H. et al. Aggressive variants of castration-resistant prostate cancer. Clin. Cancer Res. 20, 2846–2850 (2014).

pubmed: 24727321 pmcid: 4040316 doi: 10.1158/1078-0432.CCR-13-3309

Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

pubmed: 15470213 doi: 10.1056/NEJMoa040720

Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513–1520 (2004).

pubmed: 15470214 doi: 10.1056/NEJMoa041318

de Wit, R. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381, 2506–2518 (2019).

pubmed: 31566937 doi: 10.1056/NEJMoa1911206

de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).

pubmed: 20888992 doi: 10.1016/S0140-6736(10)61389-X

Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).

pubmed: 23863050 doi: 10.1056/NEJMoa1213755

Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

pubmed: 20818862 doi: 10.1056/NEJMoa1001294

Beer, T. M. et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study. Eur. Urol. 71, 151–154 (2017).

pubmed: 27477525 doi: 10.1016/j.eururo.2016.07.032

Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).

pubmed: 26000489 pmcid: 4484602 doi: 10.1016/j.cell.2015.05.001

Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428–11436 (2019).

pubmed: 31061129 doi: 10.1073/pnas.1902651116 pmcid: 6561293

Stopsack, K. H. et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 26, 3230–3238 (2020).

pubmed: 32220891 doi: 10.1158/1078-0432.CCR-20-0168 pmcid: 7334067

Nava Rodrigues, D. et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J. Clin. Invest. 128, 4441–4453 (2018).

pubmed: 30179225 pmcid: 6159966 doi: 10.1172/JCI121924

Abida, W. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 5, 471–478 (2019).

pubmed: 30589920 doi: 10.1001/jamaoncol.2018.5801

de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091–2102 (2020).

pubmed: 32343890 doi: 10.1056/NEJMoa1911440

Abida, W. et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. https://doi.org/10.1200/JCO.20.01035 (2020).

Cheng, H. H., Pritchard, C. C., Boyd, T., Nelson, P. S. & Montgomery, B. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur. Urol. 69, 992–995 (2016).

pubmed: 26724258 doi: 10.1016/j.eururo.2015.11.022

Zafeiriou, Z. et al. Genomic analysis of three metastatic prostate cancer patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency. Eur. Urol. 75, 184–192 (2019).

pubmed: 30340782 pmcid: 6291437 doi: 10.1016/j.eururo.2018.09.048

Rafiei, S. et al. ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. Cancer Res. 80, 2094–2100 (2020).

pubmed: 32127357 doi: 10.1158/0008-5472.CAN-19-3126 pmcid: 7272301

Yap, T.A. et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-20-0868 (2020).

Wu, Y. M. et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173, 1770–1782.e1714 (2018).

pubmed: 29906450 doi: 10.1016/j.cell.2018.04.034

Viswanathan, S. R. et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell 174, 433–447.e19 (2018).

pubmed: 29909985 pmcid: 6046279 doi: 10.1016/j.cell.2018.05.036

Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 175, 889 (2018).

pubmed: 30340047 doi: 10.1016/j.cell.2018.10.019

Nguyen, B. et al. Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics. Eur. Urol. https://doi.org/10.1016/j.eururo.2020.03.024 (2020).

André, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940 (2019).

pubmed: 31091374 doi: 10.1056/NEJMoa1813904

George, D. J. et al. Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. Urol. Oncol. 38, 79.e15–79.e22 (2020).

doi: 10.1016/j.urolonc.2019.08.015

Schwartz, S. et al. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell 27, 109–122 (2015).

pubmed: 25544636 doi: 10.1016/j.ccell.2014.11.008

de Bono, J. S. et al. Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin. Cancer Res. 25, 928–936 (2019).

pubmed: 30037818 doi: 10.1158/1078-0432.CCR-18-0981

Hyman, D. M. et al. AKT inhibition in solid tumors with AKT1 mutations. J. Clin. Oncol. 35, 2251–2259 (2017).

pubmed: 28489509 pmcid: 5501365 doi: 10.1200/JCO.2017.73.0143

Aggarwal, R. R. et al. Whole-genome and transcriptional analysis of treatment-emergent small-cell neuroendocrine prostate cancer demonstrates intraclass heterogeneity. Mol. Cancer Res. 17, 1235–1240 (2019).

pubmed: 30918106 pmcid: 6548614 doi: 10.1158/1541-7786.MCR-18-1101

Aparicio, A. M. et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin. Cancer Res. 22, 1520–1530 (2016).

pubmed: 26546618 doi: 10.1158/1078-0432.CCR-15-1259

Beltran, H. et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J. Clin. Invest. 130, 1653–1668 (2020).

pubmed: 32091413 pmcid: 7108892 doi: 10.1172/JCI131041

Chen, W. S. et al. Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer. Eur. Urol. 76, 562–571 (2019).

pubmed: 30928160 pmcid: 6764911 doi: 10.1016/j.eururo.2019.03.020

Hamid, A. A. et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur. Urol. 76, 89–97 (2019).

pubmed: 30553611 doi: 10.1016/j.eururo.2018.11.045

Corn, P. G. et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 20, 1432–1443 (2019).

pubmed: 31515154 pmcid: 6858999 doi: 10.1016/S1470-2045(19)30408-5

Aparicio, A. M. et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 19, 3621–3630 (2013).

pubmed: 23649003 pmcid: 3699964 doi: 10.1158/1078-0432.CCR-12-3791

Beltran, H. et al. A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin. Cancer Res. 25, 43–51 (2019).

pubmed: 30232224 doi: 10.1158/1078-0432.CCR-18-1912

Puca, L. et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci. Transl. Med. 11, eaav0891 (2019).

pubmed: 30894499 pmcid: 6525633 doi: 10.1126/scitranslmed.aav0891

Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 162, 454 (2015).

pubmed: 28843286 doi: 10.1016/j.cell.2015.06.053

Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 (2018).

pubmed: 29985747 pmcid: 6366813 doi: 10.1200/JCO.2017.77.6880

Mateo, J. et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J. Clin. Invest. 130, 1743–1751 (2020).

pubmed: 31874108 pmcid: 7108902 doi: 10.1172/JCI132031

Lovf, L. øvfM. et al. Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. Eur. Urol. 75, 498–505 (2019).

pubmed: 30181068 doi: 10.1016/j.eururo.2018.08.009

Boutros, P. C. et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736–745 (2015).

pubmed: 26005866 doi: 10.1038/ng.3315

Haffner, M. C. et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123, 4918–4922 (2013).

pubmed: 24135135 pmcid: 3809798 doi: 10.1172/JCI70354

Liu, W. et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15, 559–565 (2009).

pubmed: 19363497 pmcid: 2839160 doi: 10.1038/nm.1944

Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353–357 (2015).

pubmed: 25830880 pmcid: 4413032 doi: 10.1038/nature14347

Hong, M. K. et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 6, 6605 (2015).

pubmed: 25827447 doi: 10.1038/ncomms7605

Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369–378 (2016).

pubmed: 26928463 pmcid: 5045679 doi: 10.1038/nm.4053

Nava Rodrigues, D. et al. RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer. Clin. Cancer Res. 25, 687–697 (2019).

pubmed: 30257982 doi: 10.1158/1078-0432.CCR-18-2068

Chakraborty, G. et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin. Cancer Res. 26, 2047–2064 (2020).

pubmed: 31796516 doi: 10.1158/1078-0432.CCR-19-1570

Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78–83 (2017).

pubmed: 28059767 pmcid: 5367887 doi: 10.1126/science.aah4199

Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84–88 (2017).

pubmed: 28059768 pmcid: 5247742 doi: 10.1126/science.aah4307

Armenia, J. et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645–651 (2018).

pubmed: 29610475 pmcid: 6107367 doi: 10.1038/s41588-018-0078-z

Takeda, D. Y. et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. Cell 174, 422–432.e13 (2018).

pubmed: 29909987 pmcid: 6046260 doi: 10.1016/j.cell.2018.05.037

The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015).

pmcid: 4695400 doi: 10.1016/j.cell.2015.10.025

Ren, S. et al. Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur. Urol. 73, 322–339 (2018).

pubmed: 28927585 doi: 10.1016/j.eururo.2017.08.027

Li, J. et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature 580, 93–99 (2020).

pubmed: 32238934 doi: 10.1038/s41586-020-2135-x

Koga, Y. et al. Genomic profiling of prostate cancers from men with African and European ancestry. Clin. Cancer Res. 26, 4651–4660 (2020).

pubmed: 32651179 doi: 10.1158/1078-0432.CCR-19-4112 pmcid: 7597977

DeSantis, C. E. et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J. Clin. 66, 290–308 (2016).

pubmed: 26910411 doi: 10.3322/caac.21340

Dess, R. T. et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 5, 975–983 (2019).

pubmed: 31120534 pmcid: 6547116 doi: 10.1001/jamaoncol.2019.0826

Halabi, S. et al. Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel. J. Clin. Oncol. 37, 403–410 (2019).

pubmed: 30576268 doi: 10.1200/JCO.18.01279

Ramalingam, S. et al. Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. Urol. Oncol. 35, 418–424 (2017).

pubmed: 28126272 doi: 10.1016/j.urolonc.2016.12.016

Cecchini, M. et al. Challenges with novel clinical trial designs: master protocols. Clin. Cancer Res. 25, 2049–2057 (2019).

pubmed: 30696689 doi: 10.1158/1078-0432.CCR-18-3544

Berry, S. M., Connor, J. T. & Lewis, R. J. The platform trial: an efficient strategy for evaluating multiple treatments. J. Am. Med. Assoc. 313, 1619–1620 (2015).

doi: 10.1001/jama.2015.2316

Sailer, V. et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer 124, 1008–1015 (2018).

pubmed: 29266381 doi: 10.1002/cncr.31173

Holmes, M. G. et al. CT-guided bone biopsies in metastatic castration-resistant prostate cancer: factors predictive of maximum tumor yield. J. Vasc. Interv. Radiol. 28, 1073–1081.e1 (2017).

pubmed: 28549709 doi: 10.1016/j.jvir.2017.04.019

Lorente, D. et al. Castration-resistant prostate cancer tissue acquisition from bone metastases for molecular analyses. Clin. Genitourin. Cancer 14, 485–493 (2016).

pubmed: 27246360 pmcid: 5132155 doi: 10.1016/j.clgc.2016.04.016

Thang, S. P. et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) — a single-institution retrospective analysis. Eur. J. Nucl. Med. Mol. Imaging 45, 262–277 (2018).

doi: 10.1007/s00259-017-3821-2

Tosoian, J. J. et al. Correlation of PSMA-targeted 18F-DCFPyL PET/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer. Clin. Genitourin. Cancer 15, e65–e68 (2017).

pubmed: 27751686 doi: 10.1016/j.clgc.2016.09.002

Lambros, M. B. et al. Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis. Clin. Cancer Res. 24, 5635–5644 (2018).

pubmed: 30093450 doi: 10.1158/1078-0432.CCR-18-0862

Goodall, J. et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 7, 1006–1017 (2017).

pubmed: 28450425 pmcid: 6143169 doi: 10.1158/2159-8290.CD-17-0261

De Laere, B. et al. Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns. Eur. Urol. 72, 192–200 (2017).

pubmed: 28104311 doi: 10.1016/j.eururo.2017.01.011

Quigley, D. et al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov. 7, 999–1005 (2017).

pubmed: 28450426 pmcid: 5581695 doi: 10.1158/2159-8290.CD-17-0146

Conteduca, V. et al. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. Br. J. Cancer 123, 982–987 (2020).

pubmed: 32669676 doi: 10.1038/s41416-020-0969-5 pmcid: 7492429

Romanel, A. et al. Plasma AR and abiraterone-resistant prostate cancer. Sci. Transl. Med. 7, 312re10 (2015).

pubmed: 26537258 pmcid: 6112410 doi: 10.1126/scitranslmed.aac9511

Azad, A. A. et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res. 21, 2315–2324 (2015).

pubmed: 25712683 doi: 10.1158/1078-0432.CCR-14-2666

Wyatt, A. W. et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J. Natl. Cancer Inst. 109, djx118 (2017).

pmcid: 6440274 doi: 10.1093/jnci/djx118

Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1324 (2017).

pubmed: 29109393 pmcid: 5673918 doi: 10.1038/s41467-017-00965-y

Carreira, S. et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med. 6, 254ra125 (2014).

pubmed: 25232177 pmcid: 4422178 doi: 10.1126/scitranslmed.3009448

Annala, M. et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 8, 444–457 (2018).

pubmed: 29367197 doi: 10.1158/2159-8290.CD-17-0937

Scher, H. I. et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 33, 1348–1355 (2015).

pubmed: 25800753 pmcid: 4397279 doi: 10.1200/JCO.2014.55.3487

Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).

pubmed: 25184630 pmcid: 4201502 doi: 10.1056/NEJMoa1315815

Lambros, M. B. et al. Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis. Clin. Cancer Res. 24, 5635–5644 (2018).

pubmed: 30093450 doi: 10.1158/1078-0432.CCR-18-0862

Scher, H. I. et al. Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer. Cancer Res. 77, 5687–5698 (2017).

pubmed: 28819021 pmcid: 5666339 doi: 10.1158/0008-5472.CAN-17-1353

Keomanee-Dizon, K., Shishido, S. N. & Kuhn, P. Circulating tumor cells: high-throughput imaging of CTCs and bioinformatic analysis. Recent Results Cancer Res. 215, 89–104 (2020).

pubmed: 31605225 doi: 10.1007/978-3-030-26439-0_5 pmcid: 7679175

Beltran, H. et al. The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer. Clin. Cancer Res. 22, 1510–1519 (2016).

pubmed: 26671992 doi: 10.1158/1078-0432.CCR-15-0137

Miyamoto, D. T. et al. An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer. Cancer Discov. 8, 288–303 (2018).

pubmed: 29301747 pmcid: 6342192 doi: 10.1158/2159-8290.CD-16-1406

Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).

pubmed: 22588877 doi: 10.1158/2159-8290.CD-12-0095

Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).

pubmed: 23550210 pmcid: 4160307 doi: 10.1126/scisignal.2004088

Consortium, A. P. G. AACR Project GENIE Consortium. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017).

doi: 10.1158/2159-8290.CD-17-0151

Printz, C. AACR releases large cancer genomic data set from project GENIE. Cancer 123, 1685 (2017).

pubmed: 28475245 doi: 10.1002/cncr.30755

Kehl, K. L. et al. Assessment of deep natural language processing in ascertaining oncologic outcomes from radiology reports. JAMA Oncol. 5, 1421–1429 (2019).

pmcid: 6659158 doi: 10.1001/jamaoncol.2019.1800 pubmed: 31343664

Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. https://doi.org/10.1200/PO.17.00011 (2017).

Huang, L. et al. The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. J. Am. Med. Inform. Assoc. 24, 513–519 (2017).

pubmed: 27789569 doi: 10.1093/jamia/ocw148

Wagner, A. H. et al. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nat. Genet. 52, 448–457 (2020).

pubmed: 32246132 pmcid: 7127986 doi: 10.1038/s41588-020-0603-8

Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895–1902 (2018).

pubmed: 30137196 pmcid: 6158764 doi: 10.1093/annonc/mdy263

Knepper, T. C. et al. Key lessons learned from Moffitt’s molecular tumor board: the Clinical Genomics Action Committee experience. Oncologist 22, 144–151 (2017).

pubmed: 28179575 pmcid: 5330702 doi: 10.1634/theoncologist.2016-0195

Tafe, L. J. et al. Implementation of a molecular tumor board: the impact on treatment decisions for 35 patients evaluated at Dartmouth-Hitchcock Medical Center. Oncologist 20, 1011–1018 (2015).

pubmed: 26205736 pmcid: 4571816 doi: 10.1634/theoncologist.2015-0097

Pfister, D. G. Off-label use of oncology drugs: the need for more data and then some. J. Clin. Oncol. 30, 584–586 (2012).

pubmed: 22253470 doi: 10.1200/JCO.2011.38.5567

Nickols, N. G. et al. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 22, 531–538 (2019).

pubmed: 30804427 pmcid: 6853839 doi: 10.1038/s41391-019-0134-5

Subudhi, S. K. et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci. Transl. Med. 12, eaaz357 (2020).

doi: 10.1126/scitranslmed.aaz3577

Vlachostergios, P. J. et al. Exceptional response to pembrolizumab in a patient with castration-resistant prostate cancer with pancytopenia from myelophthisis. J. Oncol. Pract. 15, 343–345 (2019).

pubmed: 30964731 doi: 10.1200/JOP.19.00012

Mohler, J. L. et al. Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 17, 479–505 (2019).

pubmed: 31085757 doi: 10.6004/jnccn.2019.0023

Abida, W. et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis. Oncol. https://doi.org/10.1200/PO.17.00029 (2015).

McKay, R. R. et al. Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 17, 325–331 (2014).

pubmed: 25091040 pmcid: 4566855 doi: 10.1038/pcan.2014.28

Houlahan, K. E. et al. Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer. Eur. Urol. 76, 18–23 (2019).

pubmed: 30685078 doi: 10.1016/j.eururo.2018.12.036